# PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer

> **NCT01697293** · PHASE1,PHASE2 · TERMINATED · sponsor: **Prescient Therapeutics, Ltd.** · enrollment: 34 (actual)

## Conditions studied

- Breast Adenocarcinoma
- Estrogen Receptor Positive
- HER2/Neu Negative
- Recurrent Breast Carcinoma
- Stage IIB Breast Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Paclitaxel
- **PROCEDURE:** Therapeutic Conventional Surgery
- **DRUG:** Triciribine Phosphate

## Key facts

- **NCT ID:** NCT01697293
- **Lead sponsor:** Prescient Therapeutics, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-01
- **Primary completion:** 2020-06
- **Final completion:** 2020-06
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** criteria for continuing enrollment in Phase 2 portion was not met
- **Last updated:** 2020-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01697293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01697293, "PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01697293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*